Patents Assigned to ONENESS BIOTECH CO., Ltd
-
Publication number: 20240050507Abstract: A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.Type: ApplicationFiled: October 27, 2023Publication date: February 15, 2024Applicant: Oneness Biotech Co., Ltd.Inventors: Yueh-Ju Wang, Kung-Ming Lu
-
Publication number: 20240026362Abstract: Provided are interfering RNAs (e.g., siRNAs) targeting SARS-CoV (e.g., the POL, Spike, Helicase, or Envelop gene thereof) and therapeutic uses thereof for inhibiting SARS-CoV infection and/or treating diseases associated with the infection (e.g., COVID-19).Type: ApplicationFiled: December 3, 2021Publication date: January 25, 2024Applicants: MICROBIO (SHANGHAI) CO. LTD., ONENESS BIOTECH CO. LTD.Inventors: Yi-Chung CHANG, Chi-Fan YANG, Yi-Fen CHEN, Chia-Chun YANG, Yuan-Lin CHOU
-
Patent number: 11826395Abstract: A method for preparing a Plectranthus amboinicus (PA) extract, the method comprising extracting an above-ground part of Plectranthus amboinicus with an extracting solution that comprises a solvent having a suitable polarity index, filtrating and concentration the extract thus produced, and subject the concentrated extract to a chromatographic separation process using a hydrophobic interaction chromatography resin to produce the PA extract.Type: GrantFiled: June 27, 2022Date of Patent: November 28, 2023Assignee: ONENESS BIOTECH CO., LTD.Inventors: Yueh-Ju Wang, Kung-Ming Lu
-
Publication number: 20230100100Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.Type: ApplicationFiled: September 9, 2022Publication date: March 30, 2023Applicant: Oneness Biotech Co., Ltd.Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
-
Patent number: 11439682Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.Type: GrantFiled: April 29, 2020Date of Patent: September 13, 2022Assignee: Oneness Biotech Co., Ltd.Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
-
Publication number: 20210115447Abstract: Nucleic acid aptamers capable of binding to lymphocyte activation gene 3 (LAG-3) and uses thereof for modulating immune responses. Such aptamers may comprise a G-rich motif, for example, GX1GGGX2GGTX3A (SEQ ID No: 1), in which each of X1 and X2 are independently G, C, or absent, and X3 is T or C, or L-(G)n-L?, in which n is an integer of 5-9 inclusive, and L and L? are nucleotide segments having complementary sequences. Also provided herein are multimeric nucleic acid aptamers containing a backbone moiety, which comprises a palindromic sequence.Type: ApplicationFiled: June 12, 2019Publication date: April 22, 2021Applicant: Oneness Biotech Co., Ltd.Inventors: Yi-Chung CHANG, Chien-Hao CHIANG, Yi-Wei KAO
-
Publication number: 20200297815Abstract: Methods for treating a disorder associated with immunoglobulin E (IgE) in a subject with antibodies capable of binding to the C?mx domain of a membrane-bound IgE. The subject can be administered with at least two doses of the antibody, the two doses being at least three months apart.Type: ApplicationFiled: April 29, 2020Publication date: September 24, 2020Applicant: Oneness Biotech Co., Ltd.Inventors: Kung-Ming Lu, Nien-Yi Chen, Tien-Tien Cheng
-
Patent number: 10758584Abstract: The present invention provides a topical formulation comprising an active agent, which comprises salvigenin and optionally asiaticoside. The present invention also relates to the use of the topical formulation for the promotion of wound healing.Type: GrantFiled: July 17, 2017Date of Patent: September 1, 2020Assignee: Oneness Biotech Co. LTDInventors: Jen-Wei Chen, Kung-Ming Lu
-
Patent number: 10745729Abstract: Genetically engineered host animal cells capable of producing glycoproteins having modified glycosylation patterns, e.g., defucosylation and/or monoglycosylation. Such host animal cells can be engineered to express fucosidase, endoglycosidase or both.Type: GrantFiled: November 22, 2016Date of Patent: August 18, 2020Assignee: Oneness Biotech Co. Ltd.Inventors: Nien-Yi Chen, Che-Haorz Wu, Hung-Chi Chen, Winston Town
-
Patent number: 10376488Abstract: Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient.Type: GrantFiled: September 5, 2014Date of Patent: August 13, 2019Assignee: ONENESS BIOTECH CO., LTDInventors: Wei-Luen Chang, Mo-Chi Cheng
-
Patent number: 9884801Abstract: The invention relates to bioactive compounds purified from mycelium of Antrodia camphorata and the manufacturing method thereof. A method for treatment of cancers by administrating an effective amount of the said compounds selected from the group consisting of AC006, AC007, AC009, AC011, AC012, AC007-H1, AC009-H1, and AC012-H1 wherein the cancers is liver cancer, brain cancer, prostate cancer, breast cancer, colorectal cancer, or melanoma.Type: GrantFiled: December 30, 2015Date of Patent: February 6, 2018Assignee: Oneness Biotech Co., Ltd.Inventors: Chiung-Lin Liu, Wei-Tse Tsai, Kai-Hsin Hsieh
-
Publication number: 20180015133Abstract: The present invention provides a topical formulation comprising an active agent, which comprises salvigenin and optionally asiaticoside. The present invention also relates to the use of the topical formulation for the promotion of wound healing.Type: ApplicationFiled: July 17, 2017Publication date: January 18, 2018Applicant: Oneness Biotech Co. LTDInventors: Jen-Wei Chen, Kung-Ming Lu
-
Publication number: 20170273938Abstract: Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient.Type: ApplicationFiled: September 5, 2014Publication date: September 28, 2017Applicant: ONENESS BIOTECH CO., LtdInventors: Wei-Luen CHANG, Mo-Chi CHENG